Adapalene (Topical) (Monograph)
Brand name: Differin
Drug class: Keratolytic Agents
Introduction
Retinoid; synthetic naphthoic acid-derivative.7 8 10 11 12 13 14 15 16 17 18 19 20 22
Uses for Adapalene (Topical)
Acne Vulgaris
Treatment of acne vulgaris.1 4 5 6 7 11 12 13 14 16 17 18 19 20 21 22 31 32
Adapalene (Topical) Dosage and Administration
Administration
Topical Administration
Apply a thin film to skin as a cream, gel, or solution.1 4 5 7 11 12 13 16 17 18 19 20 21 22 31 32
Cleanse and dry the affected areas prior to application.1 31 32
Do not apply to eye(s), lips, angles of nose, or mucous membranes.1 31 32
A transient feeling of pruritus or burning may occur immediately after application.1 12 31 32 If increased sensitivity or irritation occurs, reduce frequency of application or, depending on the severity, discontinue use.1 31 32
Apparent exacerbation of acne that may occur during early weeks of therapy is attributable to the drug’s action on previously unseen lesions; do not discontinue.1 31 32
Excessive use does not increase therapeutic effects and may produce marked erythema, peeling, and discomfort.1 31 32
Pledgets
Remove single-use pledget applicators from foil immediately before use, use once, and then discard; do not use if seal is broken.31
Dosage
Pediatric Patients
Acne Vulgaris
Topical
Children and adolescents ≥12 years of age: Apply once daily in the evening at bedtime.1 12 31 32
Improvement usually detectable within 8–12 weeks.1 31 32
Adults
Acne Vulgaris
Topical
Apply once daily in the evening at bedtime.1 12 31 32
Improvement usually detectable within 8–12 weeks.1 31 32
Prescribing Limits
Pediatric Patients
Acne Vulgaris
Topical
Children and adolescents ≥12 years of age: most reported experience to date has been for treatment periods that did not exceed 12 weeks.4 5 6 12 22
Adults
Acne Vulgaris
Topical
Most reported experience to date has been for treatment periods that did not exceed 12 weeks.4 5 6 12 22
Cautions for Adapalene (Topical)
Contraindications
Warnings/Precautions
Sensitivity Reactions
Photosensitivity
Increased risk for sunburn; minimize exposure to sunlight or artificial UV irradiation sources (e.g., sunlamps).1 31 32
Use caution in patients subjected to considerable occupational sun exposure or with inherent sun sensitivity; use of sunscreen products (SPF 15 or greater) and protective clothing over treated areas recommended when exposure cannot be avoided.1 31 32
Avoid concomitant use of photosensitizing agents.33 (See Interactions.)
Use not recommended in patients with sunburn until full recovery occurs.1 31
Other Sensitivity Reactions
Discontinue therapy if sensitivity reaction or chemical irritation occurs.1 31 32
General Precautions
Dermatologic Effects
Erythema, dryness, scaling, burning, or pruritus may occur.1 31 32 If increased sensitivity or irritation occurs, use less frequently or, depending on the severity of the reaction, discontinue.1 31 32
Do not apply to cuts, abrasions, or eczematous or sunburned skin.1 31 32 (See Photosensitivity under Cautions.)
Facial Cleansing
Use of mild or soapless cleanser is recommended; use medicated or drying soaps and abrasive soaps and cleansers with caution.1 31 32
Cosmetic Agents or Processes
Avoid use of irritating cosmetics, other preparations, or processes (e.g., electrolysis) that might dry or irritate the skin.33 (See Interactions.)
Environmental Stimuli
Possible increased skin irritation in patients exposed to environmental extremes (e.g., wind, cold).1 31 32
Dry Skin
Use moisturizers if necessary; avoid preparations containing alpha hydroxy or glycolic acids.32
Specific Populations
Pregnancy
Lactation
Not known whether adapalene is distributed into milk.1 31 32 Use caution.1 31 32
Pediatric Use
Safety and efficacy not established in children <12 years of age.1 31 32
Geriatric Use
Insufficient experience in controlled clinical studies in patients ≥65 years of age to determine whether geriatric patients respond differently to adapalene than younger adults.32 However, clinical experience generally has not revealed age-related differences.32
Common Adverse Effects
Erythema, scaling, dryness, pruritus, burning/stinging.1 31 32
Drug Interactions
Specific Drugs
Drug |
Interaction |
Comments |
---|---|---|
Keratolytic agents (e.g., resorcinol, salicylic acid, sulfur) |
Allow sufficient time for the effects of the keratolytic agent to subside before initiating adapalene1 31 32 |
|
Photosensitizing agents (e.g., fluoroquinolone anti-infectives, phenothiazines, sulfonamides, thiazide diuretics) |
Possible increased phototoxicity33 |
Avoid concomitant use33 |
Other Topical Preparations
Potential pharmacodynamic interaction (increased skin irritation).1 31 32 Avoid concurrent use of topical preparations with high concentrations of alcohol, menthol, spices, or lime (e.g., lotions, astringents, perfume); irritating cosmetics (e.g., toners, peeling [desquamating] agents); permanent wave solutions; or hair depilatories or waxes.1 31 32 33
Adapalene (Topical) Pharmacokinetics
Absorption
Bioavailability
Minimally absorbed following topical application.1 31 32
Elimination
Elimination Route
Eliminated principally by biliary excretion.1 31 32
Stability
Storage
Topical
Cream, Gel, Solution
Protect cream from freezing.32
Store solution upright in tight container.31
Actions
-
Actions similar to those of other retinoids (e.g., isotretinoin, tretinoin) but more potent anti-inflammatory activity in vitro and in vivo.1 4 5 6 9 13 15 16 17 19 23 24 31
-
Relatively selective affinity for specific nuclear retinoic acid receptor (RAR) proteins (e.g., RARβ, RARγ) that appear to enhance gene transcription.5 6 7 23 24
-
Exact mechanism(s) of action not elucidated.1 4 5 6 9 13 15 16 17 19 31 Appears to affect expression of genes that modulate follicular keratinization5 19 22 and cell (e.g., epithelial) differentiation,1 4 5 6 9 10 13 15 19 22 23 31 which result in inhibition of corneocyte accumulation and cohesion and reduction in inflammatory and noninflammatory acne lesions.1 6 11 12 22 23 24 31
Advice to Patients
-
Importance of clinicians instructing patients about proper use of the drug.1 31 32
-
Importance of continuing therapy in early weeks, even if acne initially appears to worsen.1 31 32
-
Risk of photosensitivity; importance of using sunscreens and wearing protective clothing over treated areas.1 31 32
-
Importance of avoiding contact with eyes, lips, angles of nose, or mucous membranes.1 31 32
-
Importance of not applying adapalene to cuts, abrasions, or eczematous or sunburned skin.1 31 32
-
Importance of women informing clinicians if they are or plan to become pregnant or to breast-feed.1 31 32
-
Importance of patients informing clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs.1 31 32
-
Importance of informing patients of other important precautionary information.1 31 32 (See Cautions.)
Additional Information
The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are advised that decisions regarding use of drugs are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The manufacturer’s labeling should be consulted for more detailed information. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Topical |
Cream |
0.1% |
Differin (with parabens) |
Galderma |
Gel |
0.1% |
Differin (with methylparaben and propylene glycol) |
Galderma |
|
Pledgets (saturated with solution) |
0.1% |
Differin (with SD alcohol 40-B 30% w/v) |
Galderma |
|
Solution |
0.1% |
Differin (with SD alcohol 40-B 30% w/v) |
Galderma |
AHFS DI Essentials™. © Copyright 2025, Selected Revisions May 10, 2024. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
References
1. Galderma. Differin (adapalene) gel 0.1% prescribing information. Fort Worth, TX; 1996 May.
2. Hurwitz S. Acne vulgaris: current concepts of pathogenesis and treatment. Am J Dis Child. 1979; 133:536-44. https://pubmed.ncbi.nlm.nih.gov/155397
3. Chandraratna RAS. Tazarotene—first of a new generation of receptor-selective retinoids. Br J Dermatol. 1996; 135:18-25.
4. Verschoore M, Langner A, Wolska H et al. Efficacy and safety of CD 271 alcoholic gels in the topical treatment of acne vulgaris. Br J Dermatol. 1991; 124:368-71. https://pubmed.ncbi.nlm.nih.gov/1827344
5. Shalita A, Weiss JS, Chalker DK et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol. 1996; 34:482-5. https://pubmed.ncbi.nlm.nih.gov/8609263
6. Bernard BA. Adapalene, a new chemical entity with retinoid activity. Skin Pharmacol. 1993; 6(Suppl 1):61-9. https://pubmed.ncbi.nlm.nih.gov/8142113
7. Griffiths CEM, Elder JT, Bernard BA et al. Comparison of CD271 (Adapalene) and all- trans retinoic acid in human skin: dissociation of epidermal effects and CRABP-II mRNA expression. J Invest Dermatol. 1993; 101:325-28. https://pubmed.ncbi.nlm.nih.gov/8396608
8. Jamoulle JC, Grandjean L, Lamaud E et al. Follicular penetration and distribution of topically applied CD 271, a new naphthoic acid derivative intended for topical acne treatment. J Invest Dermatol. 1990; 94:731-2. https://pubmed.ncbi.nlm.nih.gov/2139085
9. Hensby C, Cavey D, Bouclier M et al. The in vivo and in vitro anti- inflammatory activity of CD271: a new retinoid-like modulator of cell differentiation. Agents Actions. 1990; 29:56-8. https://pubmed.ncbi.nlm.nih.gov/2109510
10. Bernerd F, Ortonne JP, Bouclier M et al. The rhino mouse model: the effects of topically applied all-trans retinoic acid and CD271 on the fine structure of the epidermis and utricle wall of pseudocomedones. Arch Dermatol Res. 1991; 283:100-7. https://pubmed.ncbi.nlm.nih.gov/2069410
11. Leyden JJ. Therapy for acne vulgaris. N Engl J Med. 1997; 336:1156-62. https://pubmed.ncbi.nlm.nih.gov/9099661
12. Brogden RN, Goa KL. Adapalene: a review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs. 1997; 53:511-9. https://pubmed.ncbi.nlm.nih.gov/9074847
13. Verschoore M. Adapalene: a novel topical retinoid receptor agonist for acne—overview. J Am Acad Dermatol. 1997; 36:S91.
14. Kligman AM. The treatment of acne with topical retinoids: one man’s opinions. J Am Acad Dermatol. 1997; 36:S92-5.
15. Shroot B, Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol. 1997; 36:S96-103. https://pubmed.ncbi.nlm.nih.gov/9204085
16. Verschoore M, Poncet M, Czernielewski J et al. Adapalene 0.1% gel has low skin- irritation potential. J Am Acad Dermatol. 1997; 36:S104-9.
17. Caron D, Sorba V, Kerrouche N et al. Split-face comparison of adapalene 0.1% gel and tretinoin 0.025% gel in acne patients. J Am Acad Dermatol. 1997; 36:S110-12. https://pubmed.ncbi.nlm.nih.gov/9204087
18. Caron D, Sorba V, Clucas A et al. Skin tolerance of adapalene 0.1% gel in combination with other topical antiacne treatments. J Am Acad Dermatol. 1997; 36:S113-5.
19. Clucas A, Verschoore M, Sorba V et al. Adapalene 0.1% gel is better tolerated than tretinoin 0.025% gel in acne patients. J Am Acad Dermatol. 1997; 36:S116-8.
20. Allec J, Chatelus A, Wagner N. Skin distribution and pharmaceutical aspects of adapalene gel. J Am Acad Dermatol. 1997; 36:S119-25. https://pubmed.ncbi.nlm.nih.gov/9204090
21. Cunliffe WJ, Caputo R, Dreno B et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials. J Am Acad Dermatol. 1997; 36:S126-34. https://pubmed.ncbi.nlm.nih.gov/9204091
22. Anon. Adapalene for acne. Med Lett Drugs Ther. 1997; 39:19-20. https://pubmed.ncbi.nlm.nih.gov/9057779
23. Thiboutot DM. Acne: an overview of clinical research findings. Dermatol Clin. 1997; 15:97-109. https://pubmed.ncbi.nlm.nih.gov/9001864
24. Gibson JR. Rationale for the development of new topical treatments for acne vulgaris. Cutis. 1996; 57:13-9. https://pubmed.ncbi.nlm.nih.gov/8654127
25. Anon. Update on birth defects with isotretinoin. FDA Drug Bull. 1984; 14:15-6. https://pubmed.ncbi.nlm.nih.gov/6592122
26. Benke PJ. The isotretinoin teratogen syndrome. JAMA. 1984; 251:3267-9. https://pubmed.ncbi.nlm.nih.gov/6587131
27. de la Cruz E, Sun S, Vangvanichyakorn K et al. Multiple congenital malformations associated with maternal isotretinoin therapy. Pediatrics. 1984; 74:428-30. https://pubmed.ncbi.nlm.nih.gov/6591112
28. Lammer EJ, Chen DT, Hoar RM et al. Retinoic acid embryopathy. N Engl J Med. 1985; 313:837-41. https://pubmed.ncbi.nlm.nih.gov/3162101
29. Rosa FW, Wilk AL, Kelsey FO. Teratogen update: vitamin A congeners. Teratology. 1986; 33:355-64. https://pubmed.ncbi.nlm.nih.gov/3461576
30. Cohen M, Rubenstein A, Li JK et al. Thymic hypoplasia associated with isotretinoin embryopathy. Am J Dis Child. 1987; 141:263-6. https://pubmed.ncbi.nlm.nih.gov/3492909
31. Galderma. Differin (adapalene) solution 0.1% prescribing information. Fort Worth, TX; 1997 Jul.
32. Galderma Laboratories. Differin cream 0.1% (adapalene) prescribing information. Fort Worth, TX; 2000 May.
33. Galderma Laboratories, Fort Worth, TX: Personal Communication.
Frequently asked questions
- What are the most common skin conditions? (with photos)
- Does doxycycline work for acne?
- Can Tazorac and Differin be used together?
More about adapalene topical
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (516)
- Side effects
- Dosage information
- During pregnancy
- Drug class: topical acne agents
- Breastfeeding
- En español